

# **Cancer Immunology Immunotherapy**

**Founding Editor**  
**G. Mathé**

**Other Biological Response Modifications**

**Volume 29 1989**

## **Editors in Chief**

**R. W. Baldwin E. Mihich**

## **Editorial Board**

**R. Arnon** Rehovot  
**R. Bast** Durham, NC  
**S. Ben-Efraim** Tel Aviv  
**J. Bennett** Albany, NY  
**N. Bloksma** Utrecht  
**H. Blythman** Basel  
**E. C. Borden** Madison, WI  
**V. S. Byers** Berkeley, CA  
**T. Carey** Ann Arbor, MI  
**M. Cheever** Seattle, WA  
**M. Colnaghi** Milan  
**S. Dray** Chicago, IL  
**S. Eccles** Sutton, Surrey  
**I. Fidler** Houston, TX

**E. Grimm** Houston, TX  
**K. Hellström** Seattle, WA  
**K. Höffken** Essen  
**J. Kieler** Copenhagen  
**H. Kirchner** Heidelberg  
**W. Knapp** Vienna  
**H. Kobayashi** Sapporo  
**M. Mastrangelo** Philadelphia, PA  
**J. McVie** Amsterdam  
**M. Mitchell** Los Angeles, CA  
**M. Moore** London  
**R. J. North** Saranac Lake, NY  
**G. Parmiani** Milan  
**M. Price** Nottingham

**R. Rees** Sheffield  
**D. Scott** Rochester, NY  
**H.-J. Senn** St. Gallen  
**K. Sikora** London  
**Z. Steplewski** Philadelphia, PA  
**G. Stevenson** Southampton  
**J. Talmadge** King of Prussia, PA  
**E. Tsubura** Osaka  
**A. Uchida** Kyoto  
**F. Vánky** Stockholm  
**E. Vitetta** Dallas, TX  
**B. Vose** Cheshire  
**Y. Yamamura** Osaka



**Springer International**

# Cancer Immunology Immunotherapy

## Other Biological Response Modifications

This journal was founded in 1976. Founding editor: G. Mathé

Editors: R. W. Baldwin, E. Mihich

Published by Springer International

### Copyright

*Submission of a manuscript implies:* that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e. g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

*Special regulations for photocopies in the USA:* Photocopies may be made for personal or inhouse use beyond the limitations stipulated under Section 107 or 108 of U. S. Copyright Law, provided a fee is paid. This fee is US \$ 0.20 per page, or a minimum of US \$ 1.00 if an article contains fewer than five pages. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0340-7004, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Printed in Germany by E. Kieser GmbH Graphischer Betrieb, D-8902 Neusäß bei Augsburg

© Springer-Verlag Berlin Heidelberg 1989

# Contents of volume 29

No. 1 (pp 1-78) published 10 April 1989  
 No. 2 (pp 79-154) published 9 May 1989  
 No. 3 (pp 155-230) published 1 June 1989  
 No. 4 (pp 231-306) published 4 July 1989

- Abe F, Schneider M, Black PL, Talmadge JE: Chemoimmunotherapy with cyclophosphamide and bestatin in experimental metastasis in mice 231
- Akiyoshi T → Nanbara S
- Akporiaye ET, Kudalore MK: Implantation of a gelatin-sponge as a model for effector recruitment. Tumor growth inhibition by T-lymphocytes recovered from a site of tumor rejection 199
- Aleksijevic A → Chong AS-F
- Altmannberger A → Bosslet K
- Altmeyer A, Moog C, Waltzinger C, Hauptmann G, Bischoff P: In vitro modulation of leucocyte function-associated antigen-1 expression on two leukemic cell lines 29
- Ames IH, Gagne GM, Garcia AM, John PA, Scatorchia GM, Tomar RH, McAfee JG: Preferential homing of tumor-infiltrating lymphocytes in tumor-bearing mice 93
- Anderson SK → Hoskin DW
- Arinaga S → Nanbara S
- Arione R → Brusa P
- Azuma E → Komada Y
- Azuma I → Saiki I
- Balch CM → Itoh K
- Ballou B → Persiani S
- Bauer BL → Bosslet K
- Baumann J → Moritz T
- Ben-Aziz R → Kedar E
- Ben-Efraim S → Shoval S
- Bernier M → Griffin TW
- Bischoff P → Altmeyer A
- Black PL → Abe F
- Blair AH → Kralovec J
- Bloksma N → van de Wiel PA
- Blomgren H: Influence of low doses of an oxazaphosphorine on natural killer activity of human lymphocytes 151
- Bokhari F → Griffin TW
- Bosslet K, Mennel HD, Rodden F, Bauer BL, Wagner F, Altmannberger A, Sedlacek HH, Wiegandt H: Monoclonal antibodies against epitopes on ganglioside GD<sub>2</sub> and its lactones. Markers for gliomas and neuroblastomas 171
- Bourel D → Martin A
- Brusa P, Pietribiasi F, Bussolati G, Dosio F, Arione R, Comoglio PM, Prat M, Cattel L: Blocked and not blocked whole-ricin-antibody immunotoxins: Intraperitoneal therapy of human tumour xenografted in nude mice 185
- Busch F → Pawelec G
- Bussolati G → Brusa P
- Calves MJ → Livingston PO
- Cattel L → Brusa P
- Cheresh D → Schibeci S
- Chong AS-F, Aleksijevic A, Scuderi P, Hersh EM, Grimes WJ: Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3<sup>+</sup>, LAK cell clones to produce interferon- $\gamma$  and tumor necrosis factor upon stimulation with tumor targets 270
- Cochran AJ → Klein JR
- Collet B → Martin A
- Collins J → Griffin TW
- Collins JL, Kao M-S: The anticancer drug, cisplatin, increases the naturally occurring cell-mediated lysis of tumor cells 17
- Comoglio PM → Brusa P
- Cummins CS → Murano EA
- Daculsi R → Vaillier D
- Dazord L → Martin A
- Desrues B → Martin A
- Doherty W → Griffin TW
- Dosio F → Brusa P
- Ehninger G → Pawelec G
- Epstein E → Kedar E
- Euhus DM, Gupta RK, Morton DL: Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine 247
- Fioretti MC → Fuschioti P
- Fisch P → Voss SD
- Fox BA, Rosenberg SA: Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires 155
- Fukui H, Reynolds CW, Lenz B, Schneider M, Talmadge JE: Mechanism of immunotherapeutic activity of OK-432 in the treatment of peritoneal carcinoma-tosis 1
- Fuschioti P, Fioretti MC, Romani L, Puccetti P: Lack of correlation between DNA-methylating activity and appearance of the immunogenic phenotype in clones of a murine lymphoma treated with mutagens 139
- Gagne GM → Ames IH
- Garcia AM → Ames IH
- Ghose T → Kralovec J
- Gionet M → Griffin TW
- Greenfield L → Griffin TW
- Griffin TW, Bokhari F, Collins J, Stochl M, Bernier M, Gionet M, Siebecker D, Wertheimer M, Groves ES, Greenfield L, Houston LL, Doherty W, Wilson J: A preliminary pharmacokinetic study of <sup>125</sup>I-labeled 260F9 anti-(breast cancer) antibody in patients 43
- Grimes WJ → Chong AS-F
- Grimm EA → Yang SC
- Groves ES → Griffin TW
- Guillemain B → Vaillier D
- Guitton C → Martin A
- Gupta RK → Euhus DM
- Hakala TR → Persiani S
- Hank JA → Voss SD
- Hasegawa A → Saiki I
- Hauptmann G → Altmeyer A
- Herberman RB → Melder RJ
- Hersey P → Schibeci S
- Hersh EM → Chong AS-F
- Hoon DSB → Klein JR
- Hoskin DW, Stankova J, Anderson SK, Roder JC: Amelioration of experimental lung metastasis in mice by therapy with anti-CD3 monoclonal antibodies 226
- Houston LL → Griffin TW
- Iida J → Saiki I
- Itoh K, Pellis NR, Balch CM: Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients 57
- Iwahashi M → Yamaue H
- Izawa T → Komada Y
- John PA → Ames IH
- Kamiya H → Komada Y
- Kao M-S → Collins JL
- Kedar E, Ben-Aziz R, Epstein E, Leshem B: Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type 74
- Kempner J → Moritz T
- Kiso M → Saiki I
- Klein E → Vanky F
- Klein JR, Hoon DSB, Nangaian J, Okun E, Cochran AJ: S-100 protein stimulates cellular proliferation 133
- Komada Y, Azuma E, Yamamoto H, Tanaka S, Shimizu K, Kamiya H, Sakurai M, Izawa T: Discontinuing therapy in childhood acute lymphoblastic leukemia treated with a chemoimmunotherapy protocol 51
- Kralovec J, Singh M, Mammen M, Blair AH, Ghose T: Synthesis of site-specific methotrexate-IgG conjugates. Comparison of stability and antitumor activity with active-ester-based conjugates 293
- Kudalore MK → Akporiaye ET
- Kuribayashi K → Yamaue H
- Kuribayashi K → Takao T
- Kurschel E → Moritz T
- Legrand E → Vaillier D
- Lenz B → Fukui H
- Leshem B → Kedar E
- Livingston PO, Ritter G, Calves MJ: Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse 179
- Lokaj J → Vorechovsky I
- Maeda H → Saiki I
- Mammen M → Kralovec J
- Martin A, Pellen P, Guitton C, Youinou P, Collet B, Desrues B, Bourel D, Dazord L, Toujas L: Characterization of the antigen identified by Po66. A mono-

- clonal antibody raised against a lung squamous cell carcinoma 118
- Masucci G, Wersäll P, Ragnhammar P, Mellstedt H: Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity 288
- May D → Moritz T
- McAfee JG → Ames IH
- McVicar DW, Merchant RE, Merchant LH, Young HF: Corticosteroids inhibit the generation of lymphokine-activated killer activity in vitro 211
- Melder RJ, Rosenfeld CS, Herberman RB, Whiteside TL: Large-scale preparation of adherent lymphokine-activated killer (A-LAK) cells for adoptive immunotherapy in man 67
- Mellstedt H → Masucci G
- Mennel HD → Bosslet K
- Merchant LH → McVicar DW
- Merchant RE → McVicar DW
- Moog C → Altmeyer A
- Morikawa Y → Takao T
- Moritz T, Niederle N, Baumann J, May D, Kurschel E, Osieka R, Kempeni J, Schlick E, Schmidt CG: Phase I study of recombinant human tumor necrosis factor  $\alpha$  in advanced malignant disease 144
- Morton DL → Euhus DM
- Munzarova M → Vorechovsky I
- Murano EA, Cummins CS: Role of respiratory-burst products from polymorphonuclear leukocytes in the antitumor activity of *Propionibacterium acnes* vaccine 7
- Murata J → Saiki I
- Nanbara S, Arinaga S, Akiyoshi T: Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients 237
- Nangaayan J → Klein JR
- Niederle N → Moritz T
- Nobis CA → Voss SD
- Ogura T → Yamasaki K
- Okun E → Klein JR
- Ophir R → Shoval S
- Osieka R → Moritz T
- Owen-Schaub L → Yang SC
- Pawelec G, Schneider E, Ehninger G, Rehbein A, Schmidt H: Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon- $\alpha$  (Wellferon) 63
- Pawelec G, Schmidt H, Rehbein A, Busch F: Antitumor activity in vitro in chronic myelogenous leukaemia revealed after treating peripheral cells with cytosine arabinoside 242
- Pellen P → Martin A
- Pellis R → Itoh K
- Persiani S, Ballou B, Shen W-C, Ryser HJ-P, Reiland JM, Hakala TR: In vivo antitumor effect of methotrexate conjugated to a monoclonal IgM antibody specific for stage-specific embryonic antigen 1, on MH-15 mouse teratocarcinoma 167
- Pieters RHH → van de Wiel PA
- Pietribiasi F → Brusa P
- Prat M → Brusa P
- Puccetti P → Fuschiotti P
- Ragnhammar P → Masucci G
- Rehbein A → Pawelec G
- Rehbein A → Pawelec G
- Reiland JM → Persiani S
- Reynolds CW → Fukui H
- Ritter G → Livingston PO
- Roberson KM → Stuhlmiller GM
- Rodden F → Bosslet K
- Roder JC → Hoskin DW
- Romani L → Fuschiotti P
- Rosenberg SA → Fox BA
- Rosenfeld CS → Melder RJ
- Roth JA → Yang SC
- Ryoyama C → Ryoyama K
- Ryoyama K, Ryoyama C: Augmented induction of antitumor cells in vivo by cyclophosphamide fails to benefit antitumor resistance of the host 255
- Ryser HJ-P → Persiani S
- Saiki I, Maeda H, Sakurai T, Murata J, Iida J, Kiso M, Hasegawa A, Azuma I: Induction of an endogenous tumor necrosis factor in mice by murine recombinant interferon- $\gamma$  combined with a lipid A subunit analog (GLA-60) of low toxicity 101
- Saito K → Yamaue H
- Saito K → Takao T
- Sakurai M → Komada Y
- Sakurai T → Saiki I
- Scatorchia GM → Ames IH
- Schibeci S, Hersey P, Cheresch D: Potentiation of interleukin-2 production and its binding by monoclonal antibodies to the gangliosides GD3 and GD2 109
- Schlick E → Moritz T
- Schmidt CG → Moritz T
- Schmidt H → Pawelec G
- Schmidt H → Pawelec G
- Schneider E → Pawelec G
- Schneider M → Fukui H
- Schneider M → Abe F
- Scuderi P → Chong AS-F
- Sedlacek HH → Bosslet K
- Seigler HF → Stuhlmiller GM
- Shen W-C → Persiani S
- Shimizu K → Komada Y
- Shoval S, Ophir R, Ben-Efraim S: Deficiency in immunocompetence of mice cured from large MOPC-315 plasmacytomas by melphalan therapy 279
- Siebeck D → Griffin TW
- Singh M → Kralovec J
- Sondel PM → Voss SD
- Sone S → Yamasaki K
- Sosman JA → Voss SD
- Stankova J → Hoskin DW
- Stochl M → Griffin TW
- Stuhlmiller GM, Roberson KM, Seigler HF: Serological response of non-human primates to human melanoma disialoganglioside GD<sub>3</sub> 205
- Tabuse K → Yamaue H
- Takao T, Morikawa Y, Kuribayashi K, Saito K: Induction of nonspecific killer cells by delayed-type hypersensitivity against soluble protein antigens in murine peritoneal cavities 219
- Talmadge JE → Fukui H
- Talmadge JE → Abe F
- Tanaka S → Komada Y
- Tani M → Yamaue H
- Tanimura H → Yamaue H
- Tomar RH → Ames IH
- Toujas L → Martin A
- Tsunoda T → Yamaue H
- Vaillier D, Daculsi R, Legrand E, Guillemain B: Production of cytokines after lipopolysaccharide stimulation of murine spleen cells during lymphoma development in AKR mice 35
- van der Pijl A → van de Wiel PA
- van de Wiel PA, Pieters RHH, van der Pijl A, Bloksma N: Synergic action between tumor necrosis factor and endotoxins or poly(A · U) on cultured bovine endothelial cells 23
- Vánky F, Klein E: Auto-tumor lysis by blood lymphocytes in vitro. Strongly activated lymphocytes lack selectivity 125
- Vorechovsky I, Munzarova M, Lokaj J: Increased bleomycin-induced chromosomal damage in lymphocytes of patients with common variable immunodeficiency indicates an involvement of chromosomal instability in their cancer predisposition 303
- Voss SD, Hank JA, Nobis CA, Fisch P, Sosman JA, Sondel PM: Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation 261
- Wagner F → Bosslet K
- Waltzinger C → Altmeyer A
- Wersäll P → Masucci G
- Wertheimer M → Griffin TW
- Whiteside TL → Melder RJ
- Wiegand H → Bosslet K
- Wilson A → Griffin TW
- Yamamoto H → Komada Y
- Yamasaki K, Sone S, Yamashita T, Ogura T: Synergistic induction of lymphokine (IL-2) activated killer activity by IL-2 and the polysaccharide lentinan, and therapy of spontaneous pulmonary metastases 87
- Yamashita T → Yamasaki K
- Yamaue H, Tanimura H, Iwashita M, Tani M, Tsunoda T, Tabuse K, Kuribayashi K, Saito K: Role of interleukin-2 and interferon- $\gamma$  in induction of activated natural killer cells from mice primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432 79
- Yang SC, Owen-Schaub L, Grimm EA, Roth JA: Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor- $\alpha$  against primary lung cancer targets 193
- Youinou P → Martin A
- Young HF → McVicar DW

